{"id":377,"date":"2025-10-16T07:30:16","date_gmt":"2025-10-16T07:30:16","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=377"},"modified":"2025-10-16T07:30:17","modified_gmt":"2025-10-16T07:30:17","slug":"china-bd-2025-haihe-biopharma-and-taiho-pharmaceutical-enters-a-license-on-pi3k%ce%b1-inhibitor-risovalisib-cyh33","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/377.html","title":{"rendered":"[China BD 2025] Haihe Biopharma and Taiho Pharmaceutical enters a License on PI3K\u03b1 Inhibitor Risovalisib (CYH33)"},"content":{"rendered":"\n<p>Announced Date: 2025-10-16 (October 16, 2025)<\/p>\n\n\n\n<p>Licensor (Seller):  HaiHe Biopharma (China)<\/p>\n\n\n\n<p>Licensee (Buyer): \u00a0Taiho Pharmaceutical\u00a0 (JP)<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Name: Risovalisib (CYH33)<\/p>\n\n\n\n<p>Asset Modality: Small Molecule<\/p>\n\n\n\n<p>Asset Target: PI3K\u03b1 inhibitor<\/p>\n\n\n\n<p>Potential Indication: ovarian clear cell carcinoma (OCCC)<\/p>\n\n\n\n<p>Current Stage: NDA in Japan, in August 2025\u00a0<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>Taiho will obtain exclusive rights in Japan to develop, manufacture and commercialize risovalisib.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>Undisclosed.<\/p>\n\n\n\n<p>Haihe will receive an upfront payment, development and sales milestone payments, and royalties based on sales revenue from Taiho.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/www.taiho.co.jp\/en\/release\/2025\/20251016.html\">Taiho Pharma Enters Into Exclusive License Agreement with Haihe Biopharma for PI3K\u03b1 Inhibitor Risovalisib (CYH33) | 2025 | TAIHO PHARMA<\/a><\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Note:<\/p>\n\n\n\n<p>Chinese Name of Haihe Biopharma \u6d77\u548c\u836f\u7269<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-10-16 (October 16, 2025) Licensor (Seller): HaiHe Biopharma (China) Licensee (Buyer): \u00a0Taiho Pharmaceutical\u00a0 (JP) &hellip; <a title=\"[China BD 2025] Haihe Biopharma and Taiho Pharmaceutical enters a License on PI3K\u03b1 Inhibitor Risovalisib (CYH33)\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/377.html\"><span class=\"screen-reader-text\">[China BD 2025] Haihe Biopharma and Taiho Pharmaceutical enters a License on PI3K\u03b1 Inhibitor Risovalisib (CYH33)<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-377","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/377","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=377"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/377\/revisions"}],"predecessor-version":[{"id":378,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/377\/revisions\/378"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=377"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=377"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=377"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}